|
Oxford BioMedica PLC - Oxford, England-based gene and cell therapy developer - Enters a five-year licensing and option agreement with Viral Vector Manufacturing Facility, an Australian contract development and manufacturing organisation (CDMO) and ‘the country’s first commercial manufacturing facility of its kind’, having signed a non-binding terms sheet in October. VVMF will have a non-exclusive global licence to use Oxford BioMedica’s inAAVate platform ‘know-how and intellectual property’, and an option to extend the licence to the LentiVector platform. OXB says it will receive a low single-digit million licence fee and is eligible for future platform use payments. Expects the contract to enable VVMF ‘to accelerate its operational and commercial readiness to provide advanced viral vector technologies to customers, capturing global demand with a particular focus on the fast-growing APAC region, and positioning Australia as a regional hub for highquality cell and gene therapy manufacturing.’ OXB Chief Business Officer Sebastien Ribault comments: ‘This agreement is a strong endorsement of OXB’s position as a world-leading viral vector CDMO. It demonstrates the robustness and adaptability of our platforms, technologies, and quality systems, enabling other organisations to benefit from the high standards we’ve established in viral vector manufacturing. Partnering with VVMF not only gives us a strategic foothold in Australia but also creates a launchpad to serve clients across the APAC region, further strengthening the global foundation for reliable AAV and lentiviral vector production.’ Current stock price: 659.00 pence, up 3.5% on Wednesday in London 12-month change: more than doubled from 306.00p Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
